EUVIMEDEUVIMED entdecken
Crossref

AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD

Grazia Pennisi, Marco Enea, Alessandra Pandolfo, Ciro Celsa, Michela Antonucci, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Stefanie Parisi, Adele Tulone, Vito Di Marco, Antonio Craxì und 2 weitere

Clinical Gastroenterology and Hepatology · 2023-05 · 21 (5) · 1293-1302.e5

DOI: 10.1016/j.cgh.2022.06.013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-05. Verfasst von Grazia Pennisi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Sezione di Gastroenterologia, PROMISE, University of Palermo, Italy. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Elasticity Imaging Techniques. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: We aimed to assess the diagnostic accuracy of AGILE 3+, a recently developed score based on the combination of aspartate aminotransferase/alanine aminotransferase ratio, platelet count, diabetes status, sex, age, and liver stiffness measurement (LSM) by transient elastography, when compared with Fibrosis-4 (FIB-4) and LSM, for the diagnosis of advanced fibrosis and for the prediction of liver-related events (LREs) occurrence in patients with NAFLD. METHODS: A total of 614 consecutive patients with biopsy-proven NAFLD or clinical diagnosis of NAFLD-related compensated cirrhosis were enrolled. LREs were recorded during follow-up. FIB-4, LSM by transient elastography (FibroScan device), and AGILE 3+ were measured. The diagnostic performance of noninvasive criteria for advanced fibrosis and for the prediction of LREs was assessed using the area under the receiver operating characteristic curve (AUROC) and decision curve analysis. RESULTS: In patients with biopsy-proven NAFLD (n = 520), LSM and AGILE 3+ had higher AUROC than FIB-4 (0.88 for LSM and AGILE 3+ vs 0.78 for FIB-4; P < .001) for advanced fibrosis, and AGILE 3+ exhibited a smaller indeterminate area in the test (25.2% for FIB-4 vs 13.1% for LSM vs 8.3% for AGILE 3+). Within the entire cohort of patients, AGILE 3+ had significantly higher AUROC for predicting LREs with respect to LSM (AUROC 36 months 0.95 vs 0.93; P =.008; 60 months 0.95 vs 0.92; P = .006; 96 months 0.97 vs 0.95; P = .001). Decision curve analysis showed that all scores had modest net benefit for ruling-out advanced fibrosis at the risk threshold of 5% to 10% where advanced fibrosis was absent. At the risk threshold of 5% of false negatives or false positives in LRE at 36, 60, 96, and 120 months, AGILE 3+ outperformed both FIB-4 and LSM for ruling out LRE. CONCLUSIONS: Depending on resource availability, clinical setting, and the risk scenarios, AGILE 3+ is an accurate and valid alternative to FIB-4 and LSM for the noninvasive assessment of disease severity and prognosis in patients with NAFLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseElasticity Imaging TechniquesHumansBiomarkersLiverLiver CirrhosisFibrosisROC CurveBiopsy

Stichwörter der Autor:innen

AGILE 3+DCAFibrosisNAFLDNASH

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Sezione di Gastroenterologia, PROMISE, University of Palermo, Italy.
  • Dipartimento di Biomedicina, Neuroscienze e Diagnostica avanzata (BIND), University of Palermo, Palermo, Italy.
  • Sezione di Gastroenterologia, PROMISE, University of Palermo, Italy. Electronic address: salvatore.petta@unipa.it.

Zitieren

APA

Pennisi, G., Enea, M., Pandolfo, A., Celsa, C., Antonucci, M., Ciccioli, C., Infantino, G., La Mantia, C., Parisi, S., Tulone, A., Di Marco, V., Craxì, A., Cammà, C., & Petta, S. (2023). AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD. Clinical Gastroenterology and Hepatology, 21(5), 1293-1302.e5. https://doi.org/10.1016/j.cgh.2022.06.013

Vancouver

Pennisi G, Enea M, Pandolfo A, Celsa C, Antonucci M, Ciccioli C, et al. AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD. Clinical Gastroenterology and Hepatology. 2023;21(5):1293-1302.e5. doi:10.1016/j.cgh.2022.06.013

BibTeX
@article{Pennisi2023,
  author = {Pennisi, Grazia and Enea, Marco and Pandolfo, Alessandra and Celsa, Ciro and Antonucci, Michela and Ciccioli, Carlo and Infantino, Giuseppe and La Mantia, Claudia and Parisi, Stefanie and Tulone, Adele and Di Marco, Vito and Craxì, Antonio and Cammà, Calogero and Petta, Salvatore},
  title = {AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {5},
  pages = {1293--1302.e5},
  doi = {10.1016/j.cgh.2022.06.013}
}
Kostenlos starten →